WHO China joint mission #COVIDー19
COVID-19 is transmitted via droplets and fomites during close unprotected contact between an infector and infectee.
who.int/docs/default-s…
COVID-19 is transmitted via droplets and fomites during close unprotected contact between an infector and infectee.
who.int/docs/default-s…
Not major drivers of transmission:
-airborne spread not been reported
(can be envisaged if certain aerosol-generating procedures are conducted in health care facilities)
-fecal shedding demonstrated from some patients, & viable virus identified in limited # case reports.
-airborne spread not been reported
(can be envisaged if certain aerosol-generating procedures are conducted in health care facilities)
-fecal shedding demonstrated from some patients, & viable virus identified in limited # case reports.
Household transmission studies underway, prelim studies ongoing in Guangdong est secondary attack rate in households ranges from 3-10%.
As COVID-19 is a newly identified pathogen, no known pre-existing immunity in humans. Everyone is assumed to be susceptible
As COVID-19 is a newly identified pathogen, no known pre-existing immunity in humans. Everyone is assumed to be susceptible
From available data, and in the absence of results from serologic studies, it is not possible to determine the extent of infection among children, what role children play in transmission, whether children are less susceptible or if they present differently clinically
~56K lab conf cases, signs and sx:
fever (87.9%), dry cough (67.7%), fatigue (38.1%), sputum production (33.4%), shortness of breath (18.6%), sore throat (13.9%), headache (13.6%), myalgia or arthralgia (14.8%), chills (11.4%), nausea or vomiting (5.0%), nasal congestion (4.8%)
fever (87.9%), dry cough (67.7%), fatigue (38.1%), sputum production (33.4%), shortness of breath (18.6%), sore throat (13.9%), headache (13.6%), myalgia or arthralgia (14.8%), chills (11.4%), nausea or vomiting (5.0%), nasal congestion (4.8%)
Most infected with COVID-19 virus have mild disease and recover. Approximately 80% of laboratory confirmed patients have had mild to moderate disease, which includes
non-pneumonia and pneumonia cases, 13.8% have severe disease and 6.1% are critical
non-pneumonia and pneumonia cases, 13.8% have severe disease and 6.1% are critical
Individuals at highest risk for severe disease & death:
People aged over 60 years and those with underlying conditions such as hypertension, diabetes, cardiovascular
disease, chronic respiratory disease and cancer.
Disease in children appears to be relatively
rare and mild
People aged over 60 years and those with underlying conditions such as hypertension, diabetes, cardiovascular
disease, chronic respiratory disease and cancer.
Disease in children appears to be relatively
rare and mild
As of 20 February, 2114 of the 55,924 laboratory confirmed cases have died (crude fatality ratio 3.8%)
The overall CFR varies by location and intensity of
transmission (i.e. 5.8% in Wuhan vs. 0.7% in other areas in China).
The overall CFR varies by location and intensity of
transmission (i.e. 5.8% in Wuhan vs. 0.7% in other areas in China).
Mortality increases with age, with the highest mortality among people over 80 years of age (CFR 21.9%). The CFR is higher among males compared to females (4.7% vs. 2.8%).
Based on available information, the median time from
symptom onset to laboratory confirmation nationally decreased from 12 days (range 8-18 days) in early January to 3 days (1-7) by early February 2020, and in Wuhan from 15 days (10-21) to 5 days (3-9), respectively.
symptom onset to laboratory confirmation nationally decreased from 12 days (range 8-18 days) in early January to 3 days (1-7) by early February 2020, and in Wuhan from 15 days (10-21) to 5 days (3-9), respectively.
Recommendations for countries with outbreaks
For the public:
